These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26678533)

  • 1. Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban.
    Durie R; Kohute M; Fernandez C; Knight M
    J Clin Pharm Ther; 2016 Feb; 41(1):92-3. PubMed ID: 26678533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient.
    King GS; Cottingham LG; Hughes RE; Ratliff PD
    J Clin Pharm Ther; 2018 Dec; 43(6):903-905. PubMed ID: 29885249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major bleeding with apixaban in atrial fibrillation: patient characteristics, management, and outcomes.
    Eisho S; Salem NM; Hoffman JL; Koerber JM; Smythe MA
    Hosp Pract (1995); 2018 Oct; 46(4):165-169. PubMed ID: 30058431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
    Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
    Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
    Dager WE; Roberts AJ; Nishijima DK
    Thromb Res; 2019 Jan; 173():71-76. PubMed ID: 30476716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence.
    Sarode R
    Clin Lab Med; 2014 Sep; 34(3):613-21. PubMed ID: 25168946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
    Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
    J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prothrombin complex concentrate administration for bleeding associated with non-vitamin K antagonist oral anticoagulants: The SAMURAI-NVAF study.
    Yoshimura S; Sato S; Todo K; Okada Y; Furui E; Matsuki T; Yamagami H; Koga M; Takahashi JC; Nagatsuka K; Arihiro S; Toyoda K;
    J Neurol Sci; 2017 Apr; 375():150-157. PubMed ID: 28320118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
    Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
    Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraosseous administration of 4-factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban.
    Ratliff P; Nutley K; Schroeder W; Cottingham L
    J Clin Pharm Ther; 2020 Jun; 45(3):577-579. PubMed ID: 31805210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
    Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
    J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists.
    Müller M; Eastline J; Nagler M; Exadaktylos AK; Sauter TC
    Scand J Trauma Resusc Emerg Med; 2019 Apr; 27(1):48. PubMed ID: 31014373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
    Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
    Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.